Dr. Li is an NIH-funded spine surgeon active in both laboratory and clinical research. He established an independent laboratory at the University of Virginia in 2004 and leads an internationally recognized program on disc degeneration and its treatment with stem cells, nanotechnology, and gene therapy.
By translating those discoveries into clinical care, he offers patients options that are current, evidence-based, and — whenever possible — less invasive than the default operation of a generation ago.
A stage-based approach to disc regeneration
In early disc degeneration, enough viable nucleus pulposus cells remain that minimally invasive non–cell-based therapies such as gene transfer or growth factor injection can be appropriate. In moderate degeneration, loss of those cells limits those approaches, and ex vivo cell-based strategies become more relevant. In advanced degeneration, when the disc is largely nonfunctional, replacement with a tissue-engineered or artificial construct is the honest next step.